Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed adenocarcinoma of the pancreas~  * No other pancreatic tumor type, including either of the following:~    * Neuroendocrine tumor~   * Acinar cell tumor~ * Metastatic disease~* Measurable disease in an area not previously irradiated~* No cerebral metastases or meningeal involvement of the tumor~PATIENT CHARACTERISTICS:~Age~* 18 to 75~Performance status~* WHO 0-1~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* Bilirubin ≤ 1.5 times upper limit of normal (biliary drainage allowed)~Renal~* Creatinine \< 120 mmol/L~Cardiovascular~* No prior myocardial infarction~* No prior angina~* No uncompensated cardiac or coronary insufficiency~* No symptomatic arrhythmia~Gastrointestinal~* No prior inflammatory bowel disease~* No prior chronic diarrhea~* No unresolved symptomatic occlusion or subocclusion of the bowel~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No ongoing active infection~* No other malignancy except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No contraindication to study treatment~* No other serious medical disorder that would preclude study treatment~* No psychiatric disorder or social or geographic situation that would preclude study participation~* Not detained or under the guardianship of another person~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy~Surgery~* Not specified~Other~* No concurrent participation in another clinical trial using therapeutic experimental agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Folfirinox (Type: EXPERIMENTAL): None
- Gemcitabine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).